Atria Investments Inc Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Atria Investments Inc bought a new stake in Grifols, S.A. (NASDAQ:GRFS) during the 3rd quarter, HoldingsChannel reports. The firm bought 38,727 shares of the biotechnology company’s stock, valued at approximately $344,000.

Several other institutional investors have also modified their holdings of GRFS. US Bancorp DE lifted its stake in shares of Grifols by 12.3% in the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock worth $183,000 after buying an additional 2,256 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Grifols by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 23,464 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 9,130 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Grifols in the third quarter valued at approximately $1,700,000. Signaturefd LLC grew its holdings in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares in the last quarter. Finally, NBC Securities Inc. grew its holdings in shares of Grifols by 2.8% in the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 1,433 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 0.4 %

Shares of NASDAQ:GRFS opened at $8.57 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15. The firm has a 50 day simple moving average of $8.86 and a 200-day simple moving average of $8.05.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.